CytoAgents Announces Completion of Cohort 1 Dose-escalation Stage of Clinical Phase 1B to Advance Research on Cytokine Release Syndrome

PITTSBURGH–(BUSINESS WIRE)–CytoAgents Inc., a clinical-stage biotechnology company developing CTO1681 for the prevention and treatment for Cytokine Release Syndrome (CRS), announced the successful completion of the first dose, core cohort dose-limiting toxicity observation period in its ongoing Phase 1b/2a clinical trial. Following a review of safety and efficacy data, the Safety Review Committee (SRC) has approved dose-escalation to the next, higher planned dose in Cohort 2.

“This milestone marks an important step forward in our mission to deliver a safe, effective therapy for Cytokine Release Syndrome,” said Teresa Whalen, RPh, CEO of CytoAgents. “We remain focused on advancing through the next stages of this trial and ultimately delivering a much-needed treatment option for patients facing this life-threatening immune response.” Read more>>